Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology

 Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology

Ligand to Acquire Ab Initio Biotherapeutics for its Antigen Technology

Shots:

  • Ligand will acquire Ab Initio for $12M in cash as Ab Initio’s antigen technology is complimenting Ligand’s OmniAb therapeutic antibody discovery platform which will further strengthen and expand ligand’s OmniAb offerings
  • In 2016, Ab Initio and Pfizer collaborated to develop AB against GPCR, post-acquisition Ligand will receive milestones and royalties on sales of targeted Abs  
  • Ligand’s OmniAb antibody platform produces naturally optimized human antibodies while Ab Initio’s antigen discovery platform targets multi-transmembrane proteins like GPCRs and advance Ab for multiple therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders

Click here to read full press release/ article | Ref: Ligand | Image: JLabs

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post